<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7317260\results\search\testTrace\results.xml">
  <result pre="be at a high risk of complications from SARS-CoV2 virus" exact="infection" post="(COVID-19). In type 2 diabetes, there is a change"/>
  <result pre="mainly in subjects with multiple comorbidities. In this respect, SARS-CoV2" exact="infection" post="may cause a more severe condition, known as COVID-19"/>
  <result pre="of pre-existing comorbidities and development of serious diseases following SARS-CoV2" exact="infection" post="[1]. Risk factors associated with development of serious morbidity"/>
  <result pre="currently widely used as effective oral hypoglycemic drugs in the" exact="treatment" post="of type-2 diabetes mellitus (T2DM). However, DPP4 inhibition has"/>
  <result pre="IL-1 Î², and IL-10 in 60 patients with T2DM; sitagliptin" exact="treatment" post="significantly decreased the high levels of pro-inflammatory TNF-Î±, and"/>
  <result pre="authors. Informed consent None. References References 1.FarsalinosKBarbouniANiauraRSystematic review of the" exact="prevalence" post="of current smoking among hospitalized COVID-19 patients in China:"/>
  <result pre="marker of activated fibroblasts and a potential target for the" exact="treatment" post="of fibrosis in Systemic SclerosisArthritis Rheumatol20207213714910.1002/art.4105831350829 20.SadikotRTRubinsteinILong-acting, multi-targeted nanomedicine:"/>
 </snippets>
</snippetsTree>
